{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T17:41:16Z","timestamp":1758044476892,"version":"3.44.0"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Fluconazole\u2013tacrolimus interactions occur, but the additional effect of ritonavir is emphasized here, underscoring the need for careful prescription reconciliation in renal transplant recipients living with HIV-AIDS to prevent accidental ritonavir coadministration and inadvertent tacrolimus toxicity. The findings provide valuable insight for therapeutic drug monitoring (TDM) specialists. Patient informed consent was obtained for publication of the anonymized data.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case presentation:<\/jats:title>\n            <jats:p>A 52-year-old male kidney transplant recipient presented to the emergency department with difficulty walking, myalgia, trouble swallowing, weakness, altered mental state, headache, loss of appetite, drowsiness, and painful oral ulcers. Laboratory results indicated an exceptionally high tacrolimus C<jats:sub>0<\/jats:sub> (139 ng\/mL), elevated serum creatinine (3.08 mg\/dL), electrolyte imbalances, and hyperglycemia. The medical team discontinued immunosuppressants, antimicrobials, and initiated supportive care. Recent use of fluconazole for the treatment of oral candidiasis was noted in medical history. Despite preemptively reducing the tacrolimus dose by nearly 57% of the original dose (1.75\u20131 mg BD), the C<jats:sub>0<\/jats:sub> remained dangerously high. On examining the pill box, the TDM physicians discovered that antiretroviral therapy had been mistakenly switched from Abacavir plus lamivudine to atazanavir plus ritonavir (a potent CYP3A inhibitor), which significantly increased tacrolimus exposure due to dual inhibition of tacrolimus metabolism by ritonavir and fluconazole. The C<jats:sub>0<\/jats:sub> began to decline 5 days after tacrolimus discontinuation. Complete uneventful clinical recovery was observed once C<jats:sub>0<\/jats:sub> dropped to 13 ng\/mL, with serum creatinine reaching a baseline of 2.1 mg\/dL. Tacrolimus was reintroduced at a starting dose of 0.25 mg BD 10 days after admission.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>This case highlights the importance of reviewing potential drug interactions before prescribing or dispensing drugs.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001366","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T18:00:35Z","timestamp":1757527235000},"page":"576-579","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Unmasking Tacrolimus Toxicity due to the Hacked Liver System"],"prefix":"10.1097","volume":"47","author":[{"given":"Priyadarshini","family":"Zula","sequence":"first","affiliation":[{"name":"Pharmacology, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Belmin B. J.","family":"Winston Gysley","sequence":"additional","affiliation":[{"name":"Renal Transplant Surgery, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashish","family":"Sharma","sequence":"additional","affiliation":[{"name":"Renal Transplant Surgery, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarbpreet","family":"Singh","sequence":"additional","affiliation":[{"name":"Renal Transplant Surgery, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shivakumar","family":"Patil","sequence":"additional","affiliation":[{"name":"Renal Transplant Surgery, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepesh Benjamin","family":"Kenwar","sequence":"additional","affiliation":[{"name":"Renal Transplant Surgery, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5548-4685","authenticated-orcid":false,"given":"Smita","family":"Pattanaik","sequence":"additional","affiliation":[{"name":"Pharmacology, and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-20250912","doi-asserted-by":"crossref","first-page":"291","DOI":"10.5937\/hpimj1503291R","article-title":"Drug-drug interactions of tacrolimus","volume":"2","author":"Rancic","year":"2015","journal-title":"Hosp Pharmacol Int Multidisciplinary J."},{"key":"R4-20250912","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1053\/jlts.2002.34880","article-title":"The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients","volume":"8","author":"Jain","year":"2002","journal-title":"Liver Transpl."},{"key":"R5-20250912","doi-asserted-by":"crossref","first-page":"e14100","DOI":"10.1111\/ctr.14100","article-title":"A retrospective cohort study exploring diltiazem as a pharmaco-enhancer for tacrolimus, in a post\u2013heart transplant setting","volume":"34","author":"Lodha","year":"2020","journal-title":"Clin Transpl."},{"key":"R7-20250912","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1136\/ejhpharm-2020-002385","article-title":"Effects of antifungal drugs on the plasma concentrations and dosage of tacrolimus in kidney transplant patients","volume":"29","author":"Cheng","year":"2022","journal-title":"Eur J Hosp Pharm Sci Pract."},{"key":"R8-20250912","doi-asserted-by":"crossref","first-page":"e13510","DOI":"10.1111\/ctr.13510","article-title":"Interactions between anti\u2010infective agents and immunosuppressants\u2014Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Sparkes","year":"2019","journal-title":"Clin Transpl."},{"key":"R9-20250912","doi-asserted-by":"crossref","first-page":"e345","DOI":"10.1093\/ajhp\/zxae032","article-title":"Phenytoin enzyme induction for management of supratherapeutic tacrolimus levels due to drug-drug interaction with nirmatrelvir\/ritonavir: case series and discussion","volume":"81","author":"Marsh","year":"2024","journal-title":"Am J Health Syst Pharm."},{"key":"R10-20250912","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2133\/dmpk.DMPK-13-RG-060","article-title":"Association between CYP3A5 genotypes in graft liver and increase in tacrolimus biotransformation from steroid treatment in living-donor liver transplant patients","volume":"29","author":"Hosohata","year":"2014","journal-title":"Drug Metab Pharmacokinet."},{"key":"R14-20250912","doi-asserted-by":"crossref","DOI":"10.1111\/jcpt.13075","article-title":"Clinically significant drug-drug interaction between tacrolimus and fluconazole in stable renal transplant recipient and literature review","volume":"45","author":"he","year":"2020","journal-title":"J Clin Pharm Therap"},{"key":"R13-20250912","doi-asserted-by":"crossref","DOI":"10.1136\/archdischild-2013-305888","article-title":"Choosing the right dose of tacrolimus","volume":"100","author":"Lancia","year":"2015","journal-title":"Arch Dis Child"},{"key":"R11-20250912","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1345\/aph.1D076","article-title":"Tacrolimus and Lopinavir\/Ritonavir interaction in liver transplantation","volume":"37","author":"Schonder","year":"2003","journal-title":"Ann Pharmacother"},{"key":"R12-20250912","first-page":"9","article-title":"Atazanavir\/ritonavir\/tacrolimus interaction","volume":"1382","year":"2011","journal-title":"React Wkly"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001366","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T12:01:59Z","timestamp":1757678519000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":11,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001366","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"type":"print","value":"0163-4356"},{"type":"electronic","value":"1536-3694"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"2025-01-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}